ALB and cancer: The C-reactive protein (CRP)/albumin (Alb) ratio (CAR) has been identified as a novel inflammation-based prognostic marker in several cancers, including esophageal cancer, lung cancer, hypopharyngeal and laryngeal cancer, and nasopharyngeal cancer6–9.